National Heart Foundation, Australia
14
2
3
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 40/100
14.3%
2 terminated/withdrawn out of 14 trials
80.0%
-6.5% vs industry average
57%
8 trials in Phase 3/4
25%
2 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
Radiotherapy vs Catheter Ablation for Ventricular Tachycardia in Structural Heart Disease
Role: collaborator
Improved Cardiovascular Disease hEALth Service Delivery in Australia: Cluster Randomised Controlled Trial (IDEAL Study)
Role: collaborator
A Clinical Trial of STAtin Therapy for Reducing Events in the Elderly (STAREE)
Role: collaborator
The EXCEL Registry of Patients Requiring ECMO
Role: collaborator
Heart Matters: The Effectiveness of Heart Health Education in Regions at Highest-risk.
Role: collaborator
VITATOPS: A Study of VITAmins TO Prevent Stroke
Role: collaborator
Radial Artery Versus Saphenous Vein Patency (RSVP) Study
Role: collaborator
Renal Denervation in Diabetes.
Role: collaborator
SCREEN-HFI (SCReening Evaluation of the Evolution of New Heart Failure Intervention Study)
Role: collaborator
The Effect of Enoxaparin Sodium on the Incidence of Deep Vein Thrombosis Following Electrophysiology Studies and Radiofrequency Ablation.
Role: collaborator
Effects of Pioglitazone Treatment on Sympathetic Nervous System Function in Metabolic Syndrome Obesity
Role: collaborator
Regulation of Lipoprotein Transport in Metabolic Syndrome
Role: collaborator
Pharmacological Regulation of Fat Transport in Metabolic Syndrome
Role: collaborator
Glycemic Load, Weight Loss and Cardiovascular Disease Risk
Role: collaborator
All 14 trials loaded